Request Free Sample ×

Kindly complete the form below to receive a free sample of this Report

* Please use a valid business email

Leading companies partner with us for data-driven Insights

clients tt-cursor
Hero Background

US Veterinary/Animal Vaccines Market

ID: MRFR/Pharma/16503-HCR
100 Pages
Satyendra Maurya
March 2026

US Veterinary Animal Vaccines Market Research Report By Type (Livestock Vaccines, Porcine Vaccines) - Growth & Industry Forecast 2025 To 2035

Share:
Download PDF ×

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

US Veterinary/Animal Vaccines Market Infographic
Purchase Options

US Veterinary/Animal Vaccines Market Summary

As per Market Research Future analysis, the US veterinary animal-vaccines market Size was estimated at 3226.23 USD Million in 2024. The US veterinary animal-vaccines market is projected to grow from 3531.43 USD Million in 2025 to 8719.24 USD Million by 2035, exhibiting a compound annual growth rate (CAGR) of 9.4% during the forecast period 2025 - 2035

Key Market Trends & Highlights

The US veterinary animal-vaccines market is experiencing robust growth driven by preventive care and technological advancements.

  • The market is witnessing an increased focus on preventive care, reflecting a shift in veterinary practices.
  • Technological advancements in vaccines are enhancing efficacy and safety, thereby attracting more pet owners.
  • Regulatory support and compliance are fostering innovation and ensuring high standards in vaccine development.
  • Rising pet ownership and growing awareness of zoonotic diseases are key drivers propelling market expansion.

Market Size & Forecast

2024 Market Size 3226.23 (USD Million)
2035 Market Size 8719.24 (USD Million)
CAGR (2025 - 2035) 9.46%

Major Players

Zoetis (US), Merck Animal Health (US), Boehringer Ingelheim (DE), Elanco Animal Health (US), Virbac (FR), Ceva Santé Animale (FR), Heska Corporation (US), Vetoquinol (FR)

Our Impact
Enabled $4.3B Revenue Impact for Fortune 500 and Leading Multinationals
Partnering with 2000+ Global Organizations Each Year
30K+ Citations by Top-Tier Firms in the Industry

US Veterinary/Animal Vaccines Market Trends

the market is currently experiencing notable growth, driven by increasing awareness of animal health and the rising prevalence of zoonotic diseases. Pet ownership has surged, leading to a heightened demand for preventive healthcare measures, including vaccinations. This trend is further supported by advancements in vaccine technology, which enhance efficacy and safety. Regulatory bodies are also playing a crucial role in ensuring that vaccines meet stringent safety standards, thereby boosting consumer confidence. As a result, veterinarians are more likely to recommend vaccinations as a vital part of routine animal care. Moreover, the market is witnessing a shift towards more personalized and targeted vaccination strategies. This approach is influenced by the growing understanding of animal immunology and the need for tailored vaccination protocols based on individual animal health profiles. Additionally, the integration of digital health solutions is becoming increasingly prevalent, allowing for better tracking of vaccination schedules and outcomes. These developments suggest a promising future for the veterinary animal-vaccines market, as stakeholders continue to prioritize animal welfare and public health initiatives.

Increased Focus on Preventive Care

There is a growing emphasis on preventive care within the veterinary animal-vaccines market. Pet owners are becoming more proactive in ensuring their animals receive necessary vaccinations, which is driven by increased awareness of the benefits of preventive healthcare. This trend is likely to continue as educational campaigns promote the importance of vaccinations in maintaining animal health.

Technological Advancements in Vaccines

Innovations in vaccine development are transforming the veterinary animal-vaccines market. New technologies are enhancing the effectiveness and safety of vaccines, leading to improved health outcomes for animals. These advancements may also facilitate the development of vaccines that target specific diseases more effectively, thereby addressing the unique health needs of various animal populations.

Regulatory Support and Compliance

Regulatory agencies are increasingly focused on ensuring the safety and efficacy of vaccines in the veterinary animal-vaccines market. Stricter compliance measures and guidelines are being implemented, which may enhance consumer trust and encourage veterinarians to adopt new vaccination protocols. This regulatory support is essential for fostering innovation and maintaining high standards in animal healthcare.

US Veterinary/Animal Vaccines Market Drivers

Rising Pet Ownership

The veterinary animal-vaccines market experiences a notable boost due to the increasing trend of pet ownership across the United States. As more households adopt pets, the demand for veterinary services, including vaccinations, escalates. Recent statistics indicate that approximately 67% of U.S. households own a pet, which translates to around 85 million families. This surge in pet ownership correlates with a heightened awareness of animal health, prompting owners to seek preventive care through vaccinations. Consequently, the veterinary animal-vaccines market is likely to expand as pet owners prioritize the health and well-being of their animals, leading to increased spending on veterinary services and products.

Increased Veterinary Expenditures

The veterinary animal-vaccines market is positively impacted by the rising expenditures on veterinary care among pet owners. Recent surveys indicate that U.S. pet owners are willing to spend more on their animals' health, with average annual veterinary expenses reaching approximately $500 per pet. This trend reflects a growing recognition of the importance of preventive care, including vaccinations, in maintaining pet health. As pet owners allocate more resources to veterinary services, the demand for vaccines is likely to rise correspondingly. This increase in veterinary expenditures not only supports the veterinary animal-vaccines market but also encourages veterinary practices to offer a wider range of vaccination options, catering to the diverse needs of pet owners.

Advancements in Vaccine Technology

Innovations in vaccine technology are reshaping the veterinary animal-vaccines market, leading to the development of more effective and safer vaccines. Recent advancements include the use of recombinant DNA technology and mRNA vaccines, which have shown promise in enhancing immune responses in animals. These technological improvements not only increase the efficacy of vaccines but also reduce the incidence of adverse reactions. As veterinary professionals become more aware of these advancements, they are likely to adopt new vaccines, thereby driving growth in the veterinary animal-vaccines market. The potential for improved animal health outcomes may encourage pet owners to invest more in vaccination, further propelling market expansion.

Legislative Support for Animal Health

Legislative measures aimed at improving animal health and welfare are playing a crucial role in the veterinary animal-vaccines market. Various states have enacted laws that mandate vaccinations for certain diseases, particularly in livestock and companion animals. This regulatory framework not only ensures higher vaccination rates but also fosters a culture of preventive care among pet owners. The American Veterinary Medical Association (AVMA) supports these initiatives, recognizing their importance in safeguarding public health and animal welfare. As compliance with vaccination laws becomes more prevalent, the veterinary animal-vaccines market is expected to benefit from increased demand for vaccines, as pet owners seek to adhere to legal requirements.

Growing Awareness of Zoonotic Diseases

The veterinary animal-vaccines market is significantly influenced by the rising awareness of zoonotic diseases, which are diseases that can be transmitted from animals to humans. As public health campaigns emphasize the importance of preventing such diseases, pet owners are becoming more proactive in vaccinating their animals. This trend is particularly relevant in urban areas where the risk of zoonotic transmission may be higher. The Centers for Disease Control and Prevention (CDC) has reported that certain zoonotic diseases, such as rabies and leptospirosis, pose serious health risks. As a result, the veterinary animal-vaccines market is likely to see increased demand for vaccines that protect against these diseases, thereby enhancing overall public health.

Market Segment Insights

By Type: Companion Animal Vaccine (Largest) vs. Bovine Vaccines (Fastest-Growing)

In the US veterinary animal-vaccines market, the distribution of market share among the various vaccine types reveals that Companion Animal Vaccines hold the largest share due to the increasing pet ownership rates and rising awareness about animal health. Following this, Bovine Vaccines have been gaining traction, particularly with the heightened focus on dairy farming efficiency and livestock protection against diseases. Growth trends indicate a robust expansion in the Bovine Vaccines sector, attributed to advancements in vaccine technology and increased investment in livestock health management. Moreover, Companion Animal Vaccines are likely to sustain their dominance with continuous innovations and a rising trend in pet healthcare spending, leading to significant demand in both areas. The interplay of these factors is shaping the future landscape of the market.

Companion Animal Vaccine (Dominant) vs. Bovine Vaccines (Emerging)

Companion Animal Vaccines cater primarily to pets like dogs and cats, reflecting strong market presence due to growing pet ownership and increased expenditure on veterinary care. This segment predominantly focuses on preventing common diseases, which reassures pet owners about their pets' health. Furthermore, innovations in vaccine formulations, including those that provide broader protection and enhanced safety profiles, reinforce this segment's dominance. Conversely, Bovine Vaccines are emerging as a critical growth area within the market, driven by the increasing demand for dairy and beef products. Enhanced breeding techniques and a rise in livestock farming to ensure high-quality meat and dairy are propelling innovations in bovine vaccine development, making them a priority for future investments.

By Disease: Companion Animal (Largest) vs. Canine (Fastest-Growing)

The US veterinary animal-vaccines market shows a diverse distribution among various disease segments, with Companion Animal leading the market in terms of share. This segment encapsulates the demand for vaccines that target diseases common to household pets, contributing significantly to the overall revenue. Following closely are Canine vaccines, which are tailored to prevent specific canine diseases. This segment also encompasses Poultry and Livestock segments, which play vital roles in preventing outbreaks in agricultural settings. In terms of growth trends, the Canine segment has emerged as the fastest-growing category, driven by increasing pet ownership and heightened awareness of preventive healthcare in pets. This growth is further amplified by advancements in vaccine technology, enhancing efficacy and safety. The Companion Animal market remains robust due to long-term trends favoring pet humanization, which continues to drive demand for veterinary care and vaccinations.

Companion Animal: Dominant vs. Canine: Emerging

The Companion Animal segment serves as the dominant force in the US veterinary animal-vaccines market, driven by a growing pet population and increasing investments in pet healthcare. Vaccines within this segment target prevalent diseases such as parvovirus and distemper, ensuring the health and longevity of pets. In contrast, the Canine segment, while still part of the larger Companion Animal category, is emerging rapidly due to specific disease targeting and a focus on preventive care. The surge in canine adoption rates, coupled with a growing emphasis on vaccination protocols, positions this segment for accelerated growth. Both segments are crucial, yet their dynamics highlight a balance between established markets and emerging opportunities.

By Technology: Live Attenuated Vaccines (Largest) vs. Recombinant Vaccines (Fastest-Growing)

In the US veterinary animal-vaccines market, Live Attenuated Vaccines dominate the landscape, accounting for a significant share due to their established efficacy and long-term immunity benefits. Meanwhile, Inactivated Vaccines and Toxoid Vaccines also command substantial market shares, reflecting the diverse needs in animal healthcare, whereas Other Vaccines play a smaller yet essential role in niche applications. Growth trends show that Recombinant Vaccines are rapidly gaining traction, driven by advancements in biotechnology and increasing incidences of infectious diseases requiring innovative solutions. Furthermore, the rising demand for effective vaccination strategies in livestock and companion animals is propelling this segment, with veterinarians increasingly adopting these cutting-edge vaccines to enhance animal health and productivity.

Technology: Live Attenuated (Dominant) vs. Recombinant (Emerging)

Live Attenuated Vaccines are well-established in the US veterinary animal-vaccines market, providing long-lasting immunity and extensive use in various animal species. Their efficacy is recognized by veterinarians, contributing to a large market share. On the other hand, Recombinant Vaccines are classified as emerging technology, gaining speed due to their capability to specifically target pathogens with fewer side effects. These vaccines showcase a potential for rapid development and use in response to outbreaks, establishing themselves as promising alternatives that align with modern veterinary practices and the need for safer, more effective vaccination methods.

Get more detailed insights about US Veterinary/Animal Vaccines Market

Key Players and Competitive Insights

The veterinary animal-vaccines market is characterized by a dynamic competitive landscape, driven by increasing demand for animal health products and a growing awareness of zoonotic diseases. Key players such as Zoetis (US), Merck Animal Health (US), and Elanco Animal Health (US) are at the forefront, each adopting distinct strategies to enhance their market presence. Zoetis (US) focuses on innovation through extensive R&D investments, aiming to develop next-generation vaccines that address emerging health challenges in livestock and companion animals. Meanwhile, Merck Animal Health (US) emphasizes strategic partnerships and collaborations to expand its product portfolio and enhance distribution channels, thereby solidifying its market position. Elanco Animal Health (US) is actively pursuing mergers and acquisitions to diversify its offerings and strengthen its competitive edge, indicating a trend towards consolidation in the market.The business tactics employed by these companies reflect a concerted effort to optimize supply chains and localize manufacturing processes. The market structure appears moderately fragmented, with several players vying for market share, yet dominated by a few key companies that wield considerable influence. This competitive environment fosters innovation and drives companies to enhance their operational efficiencies, ultimately benefiting the end consumers.
In October Zoetis (US) announced the launch of a novel vaccine targeting a prevalent viral disease in cattle, which is expected to significantly reduce mortality rates and improve herd health. This strategic move not only reinforces Zoetis's commitment to innovation but also positions the company as a leader in addressing critical health issues in livestock, potentially increasing its market share in the cattle segment.
In September Merck Animal Health (US) entered into a partnership with a leading veterinary diagnostic company to integrate advanced diagnostic tools with its vaccine offerings. This collaboration aims to provide veterinarians with comprehensive solutions that enhance disease prevention and management, thereby strengthening Merck's value proposition in the market. Such strategic alliances are indicative of a broader trend towards integrated health solutions in the veterinary sector.
In August Elanco Animal Health (US) completed the acquisition of a biotechnology firm specializing in vaccine development for companion animals. This acquisition is likely to expand Elanco's product portfolio and enhance its capabilities in the rapidly growing pet vaccine market. By integrating innovative technologies from the acquired firm, Elanco may improve its competitive positioning and respond more effectively to evolving consumer demands.
As of November the veterinary animal-vaccines market is witnessing trends such as digitalization, sustainability, and the integration of artificial intelligence in product development and distribution. Strategic alliances are increasingly shaping the competitive landscape, enabling companies to leverage shared resources and expertise. Looking ahead, competitive differentiation is expected to evolve, with a shift from price-based competition towards innovation, technological advancements, and supply chain reliability. Companies that prioritize these aspects are likely to thrive in an increasingly complex market environment.

Key Companies in the US Veterinary/Animal Vaccines Market include

Industry Developments

Ongoing developments in the US Veterinary Animal Vaccines Market have been significant, particularly in the last few months. For instance, in September 2023, Zoetis announced favorable financial results, which reflected a robust demand for its vaccine portfolio, showcasing a growth trend in the market. In October 2023, Merck Animal Health gained attention for its innovative vaccine development targeting emerging diseases, reinforcing its competitive position in the industry. The acquisition landscape also witnessed activity, with Elanco Animal Health acquiring a small biotech firm focused on vaccine-related Research and Development in July 2023 to enhance its capabilities.

Additionally, Neogen Corporation expanded its product offerings in response to rising consumer demand for reliable veterinary vaccines, emphasizing growth in this sector. Over recent years, the US Veterinary Animal Vaccines Market has experienced remarkable evolution, with major players like Pfizer Animal Health and Boehringer Ingelheim increasing investments in Research and Development, contributing to advancements in vaccine efficacy and safety. The market has successfully adapted to evolving regulations and consumer expectations, underscoring its resilience and the essential role of vaccinations in animal health management across the country.

Future Outlook

US Veterinary/Animal Vaccines Market Future Outlook

The veterinary animal-vaccines market is projected to grow at a 9.46% CAGR from 2025 to 2035, driven by increasing pet ownership, advancements in vaccine technology, and rising awareness of animal health.

New opportunities lie in:

  • Development of personalized vaccines for specific breeds and conditions. Expansion of telemedicine services for remote vaccine consultations. Investment in cold chain logistics for improved vaccine distribution efficiency.

By 2035, the veterinary animal-vaccines market is expected to achieve substantial growth and innovation.

Market Segmentation

US Veterinary/Animal Vaccines Market Type Outlook

  • Porcine Vaccines
  • Poultry Vaccine
  • Livestock Vaccine
  • Bovine Vaccines
  • Small Ruminant Vaccines
  • Companion Animal Vaccine
  • Canine Vaccine
  • Feline Vaccine
  • Aquaculture Vaccines
  • Other Animal Vaccines

US Veterinary/Animal Vaccines Market Disease Outlook

  • Porcine
  • Poultry
  • Livestock
  • Bovine
  • Small Ruminant
  • Companion Animal
  • Canine
  • Feline
  • Aquaculture

US Veterinary/Animal Vaccines Market Technology Outlook

  • Live Attenuated Vaccines
  • Inactivated Vaccines
  • Toxoid Vaccines
  • Recombinant Vaccines
  • Other Vaccines

Report Scope

MARKET SIZE 2024 3226.23(USD Million)
MARKET SIZE 2025 3531.43(USD Million)
MARKET SIZE 2035 8719.24(USD Million)
COMPOUND ANNUAL GROWTH RATE (CAGR) 9.46% (2025 - 2035)
REPORT COVERAGE Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
BASE YEAR 2024
Market Forecast Period 2025 - 2035
Historical Data 2019 - 2024
Market Forecast Units USD Million
Key Companies Profiled Zoetis (US), Merck Animal Health (US), Boehringer Ingelheim (DE), Elanco Animal Health (US), Virbac (FR), Ceva Santé Animale (FR), Heska Corporation (US), Vetoquinol (FR)
Segments Covered Type, Disease, Technology
Key Market Opportunities Advancements in mRNA technology enhance efficacy and safety in the veterinary animal-vaccines market.
Key Market Dynamics Rising demand for innovative veterinary animal vaccines driven by regulatory changes and technological advancements.
Countries Covered US
Author
Author
Author Profile
Satyendra Maurya LinkedIn
Research Analyst
An accomplished research analyst with high proficiency in market forecasting, data visualization, competitive benchmarking, and others. He holds a pronounced track record in research and consulting projects for sectors such as life sciences, medical devices, and healthcare IT. His capabilities in qualitative and quantitative analysis have resulted in positive client outcomes. Working on niche market trends, opportunities, sales, and forecasted value is part of his skill set.
Co-Author
Co-Author Profile
Garvit Vyas LinkedIn
Vice President - Operations
Garvit Vyas is a Research Analyst with experience in working across multiple industry domains in the market research sector. Over the past four years, he has been actively involved in analyzing diverse markets, gathering industry insights, and contributing to the development of comprehensive research reports. His work includes studying market trends, evaluating competitive landscapes, and supporting data-driven business insights. In the early phase of his career, Garvit worked on cross-domain research projects, which helped him build a strong foundation in market analysis, data interpretation, and industry intelligence across various sectors. Later, he transitioned into the Quality Control (QC) function, where he focuses on reviewing and refining research reports and marketing collaterals to ensure accuracy, consistency, and high editorial standards. His responsibilities include validating research data, improving report structure, and maintaining the overall quality of published content. Garvit is committed to maintaining strong research integrity and delivering reliable insights that support informed business decision-making.
Leave a Comment

FAQs

What is the current valuation of the US veterinary animal-vaccines market?

The market valuation was $3226.23 Million in 2024.

What is the projected market size for the US veterinary animal-vaccines market by 2035?

The projected valuation for 2035 is $8719.24 Million.

What is the expected CAGR for the US veterinary animal-vaccines market during the forecast period 2025 - 2035?

The expected CAGR is 9.46% during the forecast period 2025 - 2035.

Which companies are the key players in the US veterinary animal-vaccines market?

Key players include Zoetis, Merck Animal Health, Boehringer Ingelheim, Elanco Animal Health, and others.

What segment had the highest valuation in the US veterinary animal-vaccines market in 2024?

The Companion Animal Vaccine segment had a valuation of $161.31 Million in 2024.

How much is the Poultry Vaccine segment projected to grow by 2035?

The Poultry Vaccine segment is projected to grow from $483.73 Million in 2024 to $1285.12 Million by 2035.

What type of vaccine technology is expected to dominate the market?

Inactivated Vaccines are expected to dominate, with a projected valuation of $2100.00 Million by 2035.

What is the valuation range for Bovine Vaccines in the US veterinary animal-vaccines market?

The valuation range for Bovine Vaccines is $483.73 Million to $1285.12 Million.

What is the market size for Aquaculture Vaccines in 2024?

The market size for Aquaculture Vaccines was $161.31 Million in 2024.

How does the market for Live Attenuated Vaccines compare to other vaccine technologies?

Live Attenuated Vaccines had a valuation of $500.00 Million in 2024, indicating strong market presence.

Download Free Sample

Kindly complete the form below to receive a free sample of this Report

Compare Licence

×
Features License Type
Single User Multiuser License Enterprise User
Price $4,950 $5,950 $7,250
Maximum User Access Limit 1 User Upto 10 Users Unrestricted Access Throughout the Organization
Free Customization
Direct Access to Analyst
Deliverable Format
Platform Access
Discount on Next Purchase 10% 15% 15%
Printable Versions